Showing 9221-9230 of 20873 results for "".
Managing Immune-Related Adverse Events in Metastatic NSCLC
https://reachmd.com/programs/project-oncology/managing-iraes-metastatic-nsclc/49119/Immunotherapy-based combination regimens continue to transform the treatment landscape for metastatic non-small cell lung cancer (NSCLC). However, long-term safety findings from trials like KEYNOTE-189, CheckMate 9LA, and IMpower150 show that grade 3 or higher immune-related adverse events can occurHow Selective Photothermolysis Was Introduced in Dermatology
https://reachmd.com/programs/modern-aesthetics-focus-on-energy-based-devices/talking-fractional-lasers-with-the-inventor/56541/Laser pioneer R. Rox Anderson, MD, FAAD, joins Modern Aesthetics March/April Guest Medical Editor Jill Waibel, FACS, FAAD, to discuss the invention of fractional lasers and the impact of that technology on the field.Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
https://reachmd.com/programs/project-oncology/bringing-cancer-care-home-how-subcutaneous-immunotherapy-can-help-ease-the-burden/35770/As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the at-home administration of subcutaneous formulations of immunotherapy agents like atezolizumab could help transform the way we care forComprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
https://reachmd.com/programs/neurofrontiers/comprehensive-care-navigating-neurobehavioral-issues-in-dmd-patients/16502/Here are some best practices for managing the 70 percent of patients with Duchenne muscular dystrophy who also have a neurobehavioral issue.Matching TNBC Treatment Intensity to Patient Needs
https://reachmd.com/programs/project-oncology/matching-tnbc-treatment-intensity-patient-needs/50995/As most patients with early-stage triple-negative breast cancer (TNBC) receive multiple systemic therapies before surgery, an important question remains: how can treatment intensity be better aligned with individual patient needs? That was the focus of Dr. Roberto Leon-Ferre’s session at the 2026 AmWhen to Adjust Treatment in Irritable Bowel Syndrome with Constipation
https://reachmd.com/programs/clinicians-roundtable/adjust-treatment-irritable-bowel-syndrome-constipation/51045/Knowing when to adjust treatment in patients with irritable bowel syndrome with constipation (IBS-C) can make a meaningful difference in outcomes. However, various challenges can make it difficult to find the right moment to reassess and pivot therapy. To make the process a little simpler, Dr. BrianHow Advances in Immunology Are Shaping CSU Care
https://reachmd.com/programs/on-the-frontlines-of-chronic-spontaneous-urticaria/how-advances-in-immunology-are-shaping-csu-care/56724/Chronic spontaneous urticaria (CSU) involves distinct immune mechanisms that set it apart from other inflammatory skin diseases, and advances in our understanding of cytokines and mast cell activation are reshaping how clinicians approach its diagnosis and treatment. Joining Dr. Steve Jackson to expThe Intersection of Dry Eye and Allergies
https://reachmd.com/podcasts/to-the-point/the-intersection-of-dry-eye-and-allergies/56799/Co-hosts Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, FAAO, invite Mila Ioussifova, OD, CNS, FAAO, FOWNS, back on the To the Point podcast to talk about in-office allergy testing. Dr. Ioussifova has built her dry eye and ocular allergy treatment armamentarium over the course of 13 years in pracStrengthening Global Infrastructure for FSHD Trials
https://reachmd.com/programs/Audioabstracts/global-infrastructure-fshd-trials/54642/As global clinical trials for facioscapulohumeral muscular dystrophy (FSHD) expand, initiatives like Project Mercury are addressing key challenges in building international research infrastructure and site readiness. Tune in to hear Dr. Mimi Maeusli explore how global collaboration is accelerating tThe Future of Immunotherapy: Advancing Care in Endometrial Cancer
https://reachmd.com/programs/project-oncology/future-immunotherapy-endometrial-cancer/39932/Immunotherapy is a key treatment option for advanced and recurrent endometrial cancer, yet response rates remain variable—even in patients with mismatch repair-deficient tumors. Hear from Dr. Casey Cosgrove as he explores emerging strategies to enhance immune responsiveness, better predict tr